Navigation Links
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Date:9/20/2007

and renal dysfunction.

Adverse events were mild or moderate in severity, and there were no differences in the rates of clinically meaningful serious adverse events across the study groups. However, discontinuations due to AEs were highest among patients given conivaptan 80 mg/day and were largely attributed to local infusion-site reactions.

Note: These study results were presented at the 2004 annual meeting of the Heart Failure Society of America in Toronto.

About Hyponatremia

Hyponatremia often results from elevated levels of the hormone arginine vasopressin (AVP), which regulates water and salt balance in the body. It is the most common electrolyte disorder in clinical medicine and one of the most difficult to treat.

Syndrome of inappropriate antidiuretic hormone (SIADH), advanced kidney failure, hypothyroidism, cancer and chronic high blood pressure are common causes of hyponatremia. Dilutional hyponatremia, which includes euvolemic and hypervolemic hyponatremia, is the most common form of the condition, and occurs when retained water dilutes serum sodium content. Patients with hyponatremia are classified as hypervolemic if swelling of body tissues (edema) is present or euvolemic if there is an increase in total body water content without edema.(1,2)

About VAPRISOL

Discovered and developed by Astellas Pharma Inc. headquartered in Tokyo, Japan, VAPRISOL is a novel drug that blocks the activity of AVP, resulting in increased urine output without loss of valuable electrolytes such as sodium and potassium. This effect, known as "aquaresis," helps to increase serum sodium levels in patients with hyponatremia, a condition of low serum sodium concentration, due to increased body water (dilutional hyponatremia). VAPRISOL is the first AVP receptor antagonist with a demonstrated safety profile and that effectively promotes aquaresis which helps to restore salt and water balance in patients with euvolemic and hypervolemic hyponatrem
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014  Market research firm Kalorama ... "Year of The Buy, in the medical device industry.  ... medical devices will produce just 3% growth this year, ... including acquisitions of product lines and entrance by acquisition ... survey of medical devices, The Global Market for ...
(Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
(Date:11/21/2014)... Nov. 20, 2014 Oxis International, Inc. (OXIS) (OXI.PA) ... election of Anthony J. Cataldo as Chief Executive ... Effective November 19, 2014, Ken Eaton resigned his ... of Directors of Oxis International, Inc. to pursue new opportunities. ... named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3
... Dec. 29 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... the treatment of cardiovascular and metabolic disease, today announced that ... the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") ... would be suspended prior to the open of business on ...
... , , ... a leading developer of medical device technology for the ... a new Webinar program supporting its culture of safety ... titled "A Culture of Safety in Pharmacy: Lessons Learned," ...
Cached Medicine Technology:VIA Pharmaceuticals Receives Delisting Notification From NASDAQ 2VIA Pharmaceuticals Receives Delisting Notification From NASDAQ 3VIA Pharmaceuticals Receives Delisting Notification From NASDAQ 4VIA Pharmaceuticals Receives Delisting Notification From NASDAQ 5Baxa Corporation to Sponsor Free Culture of Safety Webinar 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 3
(Date:11/22/2014)... 22, 2014 “Greenfield Naturals” was featured ... Report , which features the latest and coolest technology ... and reporter for NewsWatch, conducted the product review and ... flavor of your water. , From pollution to hazardous ... that everything is done to remove these chemicals, especially ...
(Date:11/22/2014)... (HealthDay News) -- Many young people consider hookahs a ... study finds fumes from the water pipes contain the ... increased risk for leukemia in prior research, according to ... Cancer Epidemiology, Biomarkers & Prevention . "In ... not a safe alternative to smoking other forms of ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, ... homes may commonly deal with aggressive or inappropriate behavior from ... 10 centers in New York state found that, in the ... were involved in some type of incident with a fellow ... someone yelling or cursing at another resident. In other cases, ...
(Date:11/21/2014)... 20, 2014 (HealthDay News) -- Seeking to make it ... Food and Drug Administration on Thursday approved a new ... Hydrocodone -- best known by the brand name Vicodin ... tied to a surge in dangerous addictions across the ... Hysingla ER (hydrocodone bitartrate) is an extended-release tablet to ...
(Date:11/21/2014)... November 21, 2014 Richard Wolfe, ... , will present advanced benefits administration strategies during ... Houston HR Leadership Summit. This Game Changer breakout ... industry to present cutting-edge solutions and best practices ... explain how real-time data exchange between health and ...
Breaking Medicine News(10 mins):Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3
... difference between upbeat, less positive patients , , MONDAY, Oct. ... states predict how long a person with cancer will ... researchers say that among head and neck cancer patients, ... an independent factor affecting prognosis. , "We anticipated finding ...
... 2007; Company Prepares for ... Integration of Organon BioSciences, KENILWORTH, N.J., Oct. ... results for the third,quarter of 2007 and commented on its ... human health business,and Intervet animal health business. "Schering-Plough has ...
... Leading Employers Adopts InterviewDirect to ... Customer Support Positions, CHERRY HILL, N.J., ... provider of telephone-based job candidate screening solutions,today ... has selected,its InterviewDirect service to pre-qualify job ...
... (Oct. 22, 2007)Work done in part by researchers ... has led to the discovery of two genes that ... The findings are published in the Oct. 21 ... research on the genetic basis for common and complex ...
... bay, experts say , , SUNDAY, Oct. 21 (HealthDay News) -- ... a treat for both children and adults, according to experts ... Chicago. , "We can keep Halloween safe for everyone by ... senior vice president, said in a prepared statement. "Our vision ...
... new pledges of,commitment to invest in women,s ... and non-governmental organizations,today at closing sessions of ... mobilize political will and investment to reduce,pregnancy-related ... 1,800 participants from 109 countries cheered a ...
Cached Medicine News:Health News:Emotional State Doesn't Affect Cancer Survival 2Health News:Emotional State Doesn't Affect Cancer Survival 3Health News:Emotional State Doesn't Affect Cancer Survival 4Health News:Emotional State Doesn't Affect Cancer Survival 5Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 2Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 3Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 4Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 5Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 6Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 7Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 8Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 9Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 10Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 11Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 12Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 13Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 14Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 15Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 16Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 17Health News:Schering-Plough Reports Financial Results for Third Quarter of 2007 18Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 2Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 3Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 2Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 3Health News:Eye on Safety Makes Halloween Less Scary 2Health News:Women Deliver Conference Launches New Commitments 2
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
MONOJECT Brown Stopper...
Medicine Products: